Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium

Suzanne C Dixon; Christina M Nagle; Nicolas Wentzensen; Britton Trabert; Alicia Beeghly-Fadiel; Joellen M Schildkraut; Kirsten B Moysich; Anna deFazio; Harvey A Risch; Mary Anne Rossing; Jennifer A Doherty; Kristine G Wicklund; Marc T Goodman; Francesmary Modugno; Roberta B Ness; Robert P Edwards; Allan Jensen; Susanne K Kjær; Estrid Høgdall; Andrew Berchuck; Daniel W Cramer; Kathryn L Terry; Elizabeth M Poole; Elisa V Bandera; Lisa E Paddock; Hoda Anton-Culver; Argyrios Ziogas; Usha Menon; Simon A Gayther; Susan J Ramus; Aleksandra Gentry-Maharaj; Celeste Leigh Pearce; Anna H Wu; Malcolm C Pike; Penelope M Webb; Australian Ovarian Cancer Study Group

doi:10.1038/bjc.2017.68

Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium

Suzanne C Dixon, Christina M Nagle, Nicolas Wentzensen, Britton Trabert, Alicia Beeghly-Fadiel, Joellen M Schildkraut, Kirsten B Moysich, Anna deFazio, Harvey A Risch, Mary Anne Rossing, Jennifer A Doherty, Kristine G Wicklund, Marc T Goodman, Francesmary Modugno, Roberta B Ness, Robert P Edwards, Allan Jensen, Susanne K Kjær, Estrid Høgdall, Andrew BerchuckDaniel W Cramer, Kathryn L Terry, Elizabeth M Poole, Elisa V Bandera, Lisa E Paddock, Hoda Anton-Culver, Argyrios Ziogas, Usha Menon, Simon A Gayther, Susan J Ramus, Aleksandra Gentry-Maharaj, Celeste Leigh Pearce, Anna H Wu, Malcolm C Pike, Penelope M Webb, Australian Ovarian Cancer Study Group

Department of Clinical Medicine

11 Citations (Scopus)

37 Downloads (Pure)

Abstract

BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) have been associated with improved survival in some cancers, but evidence for ovarian cancer is limited.

METHODS: Pooling individual-level data from 12 Ovarian Cancer Association Consortium studies, we evaluated the association between self-reported, pre-diagnosis use of common analgesics and overall/progression-free/disease-specific survival among 7694 women with invasive epithelial ovarian cancer (4273 deaths).

RESULTS: Regular analgesic use (at least once per week) was not associated with overall survival (pooled hazard ratios, pHRs (95% confidence intervals): aspirin 0.96 (0.88-1.04); non-aspirin NSAIDs 0.97 (0.89-1.05); acetaminophen 1.01 (0.93-1.10)), nor with progression-free/disease-specific survival. There was however a survival advantage for users of any NSAIDs in studies clearly defining non-use as less than once per week (pHR=0.89 (0.82-0.98)).

CONCLUSIONS: Although this study did not show a clear association between analgesic use and ovarian cancer survival, further investigation with clearer definitions of use and information about post-diagnosis use is warranted.

Original language	English
Journal	B J C
Volume	116
Issue number	9
Pages (from-to)	1223-1228
ISSN	0007-0920
DOIs	https://doi.org/10.1038/bjc.2017.68
Publication status	Published - 25 Apr 2017

Keywords

Acetaminophen/therapeutic use
Adult
Aged
Analgesics/therapeutic use
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
Anticarcinogenic Agents/therapeutic use
Aspirin/therapeutic use
Disease-Free Survival
Female
Humans
Middle Aged
Ovarian Neoplasms/drug therapy
Proportional Hazards Models
Risk Factors

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/bjc.2017.68Licence: CC BY-NC-SA

Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association ConsortiumFinal published version, 442 KBLicence: CC BY-NC-SA

Cite this

Dixon, S. C., Nagle, C. M., Wentzensen, N., Trabert, B., Beeghly-Fadiel, A., Schildkraut, J. M., Moysich, K. B., deFazio, A., Risch, H. A., Rossing, M. A., Doherty, J. A., Wicklund, K. G., Goodman, M. T., Modugno, F., Ness, R. B., Edwards, R. P., Jensen, A., Kjær, S. K., Høgdall, E., ... Australian Ovarian Cancer Study Group (2017). Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. B J C, 116(9), 1223-1228. https://doi.org/10.1038/bjc.2017.68

Dixon, SC, Nagle, CM, Wentzensen, N, Trabert, B, Beeghly-Fadiel, A, Schildkraut, JM, Moysich, KB, deFazio, A, Risch, HA, Rossing, MA, Doherty, JA, Wicklund, KG, Goodman, MT, Modugno, F, Ness, RB, Edwards, RP, Jensen, A, Kjær, SK , Høgdall, E, Berchuck, A, Cramer, DW, Terry, KL, Poole, EM, Bandera, EV, Paddock, LE, Anton-Culver, H, Ziogas, A, Menon, U, Gayther, SA, Ramus, SJ, Gentry-Maharaj, A, Pearce, CL, Wu, AH, Pike, MC, Webb, PM & Australian Ovarian Cancer Study Group 2017, 'Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium', B J C, vol. 116, no. 9, pp. 1223-1228. https://doi.org/10.1038/bjc.2017.68

@article{5c5e7817a8bc482d9c219f222d1555bf,

title = "Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium",

abstract = "BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) have been associated with improved survival in some cancers, but evidence for ovarian cancer is limited.METHODS: Pooling individual-level data from 12 Ovarian Cancer Association Consortium studies, we evaluated the association between self-reported, pre-diagnosis use of common analgesics and overall/progression-free/disease-specific survival among 7694 women with invasive epithelial ovarian cancer (4273 deaths).RESULTS: Regular analgesic use (at least once per week) was not associated with overall survival (pooled hazard ratios, pHRs (95% confidence intervals): aspirin 0.96 (0.88-1.04); non-aspirin NSAIDs 0.97 (0.89-1.05); acetaminophen 1.01 (0.93-1.10)), nor with progression-free/disease-specific survival. There was however a survival advantage for users of any NSAIDs in studies clearly defining non-use as less than once per week (pHR=0.89 (0.82-0.98)).CONCLUSIONS: Although this study did not show a clear association between analgesic use and ovarian cancer survival, further investigation with clearer definitions of use and information about post-diagnosis use is warranted.",

keywords = "Acetaminophen/therapeutic use, Adult, Aged, Analgesics/therapeutic use, Anti-Inflammatory Agents, Non-Steroidal/therapeutic use, Anticarcinogenic Agents/therapeutic use, Aspirin/therapeutic use, Disease-Free Survival, Female, Humans, Middle Aged, Ovarian Neoplasms/drug therapy, Proportional Hazards Models, Risk Factors",

author = "Dixon, {Suzanne C} and Nagle, {Christina M} and Nicolas Wentzensen and Britton Trabert and Alicia Beeghly-Fadiel and Schildkraut, {Joellen M} and Moysich, {Kirsten B} and Anna deFazio and Risch, {Harvey A} and Rossing, {Mary Anne} and Doherty, {Jennifer A} and Wicklund, {Kristine G} and Goodman, {Marc T} and Francesmary Modugno and Ness, {Roberta B} and Edwards, {Robert P} and Allan Jensen and Kj{\ae}r, {Susanne K} and Estrid H{\o}gdall and Andrew Berchuck and Cramer, {Daniel W} and Terry, {Kathryn L} and Poole, {Elizabeth M} and Bandera, {Elisa V} and Paddock, {Lisa E} and Hoda Anton-Culver and Argyrios Ziogas and Usha Menon and Gayther, {Simon A} and Ramus, {Susan J} and Aleksandra Gentry-Maharaj and Pearce, {Celeste Leigh} and Wu, {Anna H} and Pike, {Malcolm C} and Webb, {Penelope M} and {Australian Ovarian Cancer Study Group}",

year = "2017",

month = apr,

day = "25",

doi = "10.1038/bjc.2017.68",

language = "English",

volume = "116",

pages = "1223--1228",

journal = "The British journal of cancer. Supplement",

issn = "0007-0920",

publisher = "nature publishing group",

number = "9",

}

TY - JOUR

T1 - Use of common analgesic medications and ovarian cancer survival

T2 - results from a pooled analysis in the Ovarian Cancer Association Consortium

AU - Dixon, Suzanne C

AU - Nagle, Christina M

AU - Wentzensen, Nicolas

AU - Trabert, Britton

AU - Beeghly-Fadiel, Alicia

AU - Schildkraut, Joellen M

AU - Moysich, Kirsten B

AU - deFazio, Anna

AU - Risch, Harvey A

AU - Rossing, Mary Anne

AU - Doherty, Jennifer A

AU - Wicklund, Kristine G

AU - Goodman, Marc T

AU - Modugno, Francesmary

AU - Ness, Roberta B

AU - Edwards, Robert P

AU - Jensen, Allan

AU - Kjær, Susanne K

AU - Høgdall, Estrid

AU - Berchuck, Andrew

AU - Cramer, Daniel W

AU - Terry, Kathryn L

AU - Poole, Elizabeth M

AU - Bandera, Elisa V

AU - Paddock, Lisa E

AU - Anton-Culver, Hoda

AU - Ziogas, Argyrios

AU - Menon, Usha

AU - Gayther, Simon A

AU - Ramus, Susan J

AU - Gentry-Maharaj, Aleksandra

AU - Pearce, Celeste Leigh

AU - Wu, Anna H

AU - Pike, Malcolm C

AU - Webb, Penelope M

AU - Australian Ovarian Cancer Study Group

PY - 2017/4/25

Y1 - 2017/4/25

N2 - BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) have been associated with improved survival in some cancers, but evidence for ovarian cancer is limited.METHODS: Pooling individual-level data from 12 Ovarian Cancer Association Consortium studies, we evaluated the association between self-reported, pre-diagnosis use of common analgesics and overall/progression-free/disease-specific survival among 7694 women with invasive epithelial ovarian cancer (4273 deaths).RESULTS: Regular analgesic use (at least once per week) was not associated with overall survival (pooled hazard ratios, pHRs (95% confidence intervals): aspirin 0.96 (0.88-1.04); non-aspirin NSAIDs 0.97 (0.89-1.05); acetaminophen 1.01 (0.93-1.10)), nor with progression-free/disease-specific survival. There was however a survival advantage for users of any NSAIDs in studies clearly defining non-use as less than once per week (pHR=0.89 (0.82-0.98)).CONCLUSIONS: Although this study did not show a clear association between analgesic use and ovarian cancer survival, further investigation with clearer definitions of use and information about post-diagnosis use is warranted.

AB - BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) have been associated with improved survival in some cancers, but evidence for ovarian cancer is limited.METHODS: Pooling individual-level data from 12 Ovarian Cancer Association Consortium studies, we evaluated the association between self-reported, pre-diagnosis use of common analgesics and overall/progression-free/disease-specific survival among 7694 women with invasive epithelial ovarian cancer (4273 deaths).RESULTS: Regular analgesic use (at least once per week) was not associated with overall survival (pooled hazard ratios, pHRs (95% confidence intervals): aspirin 0.96 (0.88-1.04); non-aspirin NSAIDs 0.97 (0.89-1.05); acetaminophen 1.01 (0.93-1.10)), nor with progression-free/disease-specific survival. There was however a survival advantage for users of any NSAIDs in studies clearly defining non-use as less than once per week (pHR=0.89 (0.82-0.98)).CONCLUSIONS: Although this study did not show a clear association between analgesic use and ovarian cancer survival, further investigation with clearer definitions of use and information about post-diagnosis use is warranted.

KW - Acetaminophen/therapeutic use

KW - Adult

KW - Aged

KW - Analgesics/therapeutic use

KW - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use

KW - Anticarcinogenic Agents/therapeutic use

KW - Aspirin/therapeutic use

KW - Disease-Free Survival

KW - Female

KW - Humans

KW - Middle Aged

KW - Ovarian Neoplasms/drug therapy

KW - Proportional Hazards Models

KW - Risk Factors

U2 - 10.1038/bjc.2017.68

DO - 10.1038/bjc.2017.68

M3 - Letter

C2 - 28350790

SN - 0007-0920

VL - 116

SP - 1223

EP - 1228

JO - The British journal of cancer. Supplement

JF - The British journal of cancer. Supplement

IS - 9

ER -

Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this